| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers V > Headlines for Vasogen Inc. > News item |
Vasogen reports Celacade cuts time in hospital for heart failure patients
New York, Sept. 13 - Vasogen Inc. said data from its Acclaim trial of Celacade for chronic heart failure showed the drug reduced the average days spent in hospital by 32% in the prime target of heart failure patients.
"The ability of Celacade to significantly reduce time in hospital, in conjunction with reducing the risk of death or cardiovascular hospitalization for this important group of heart failure patients, underscores the robustness and consistency of the Acclaim data," said Guillermo Torre-Amione, medical director of the heart transplant programat Methodist DeBakey Heart Center at The Methodist Hospital and principal investigator for the U.S. arm of the trial.
"The need for repeated hospitalizations remains a persistent problem for heart failure patients, resulting in reduced quality of life and a major drain on healthcare resources. A therapy that not only reduces the risk of death or first cardiovascular hospitalization, but also reduces the total days spent in hospital by a similar magnitude, would be a welcome addition to the standard of care."
Vasogen said it is now preparing for a meeting with the Food and Drug Administration to discuss plans for a regulatory submission for approval in the United States. The Mississauga, Ont., company also said it is making progress in discussions with prospective marketing partners to support commercialization of Celacade in the European Union.
In addition to the reduction in hospital time, the trial also showed Celacade reduced the risk of death or first cardiovascular hospitalization for patients with no prior history of a heart attack.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.